SOPHiA GENETICS SASOPHEarnings & Financial Report
Sophia Genetics SA is a Swiss-founded data-driven medicine software company with headquarters in Rolle, Switzerland and Boston, Massachusetts, as well as offices in France. It provides genomic and radiomic, and multimodal analysis for hospitals, laboratories, and biopharma institutions.
SOPH Q3 2025 Key Financial Metrics
Revenue
$19.5K
Gross Profit
$12.9K
Operating Profit
$-17.9K
Net Profit
N/A
Gross Margin
66.3%
Operating Margin
-91.8%
Net Margin
N/A
YoY Growth
N/A
Financial Flow
SOPHiA GENETICS SA Q3 2025 Financial Summary
SOPHiA GENETICS SA reported revenue of $19.5K for Q3 2025, with a net profit of N/A (N/A margin). Cost of goods sold was $6.6K, operating expenses totaled $30.8K.
Key Financial Metrics
| Total Revenue | $19.5K |
|---|---|
| Net Profit | N/A |
| Gross Margin | 66.3% |
| Operating Margin | -91.8% |
| Report Period | Q3 2025 |
SOPHiA GENETICS SA Annual Revenue by Year
SOPHiA GENETICS SA annual revenue history includes year-by-year totals (for example, 2024 revenue was $15.9M).
| Year | Annual Revenue |
|---|---|
| 2024 | $15.9M |
Income Statement
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16303 | $15779 | $15808 | $15.9M | $17733 | $17.8M | $18323 | $19462 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $243838 | $206156 | $181.1M | $206.2M | $155.3M | $155.3M | $177.6M | $155309 |
| Liabilities | $43708 | $54714 | $59.7M | $54.7M | $58.8M | $58.8M | $100.9M | $58819 |
| Equity | $200130 | $151442 | $121.4M | $151.4M | $96.5M | $96.5M | $76.7M | $96490 |
Cash Flow
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-39872 | $-14644 | $-25044 | $-33.5M | $-43979 | $-10.7M | $-27552 |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M